Chemical Formula: C11H15N5O4
Chemical Formula C11H15N5O4
Found 67 metabolite its formula value is C11H15N5O4
1-Methyladenosine
C11H15N5O4 (281.11239900000004)
1-Methyladenosine, also known as M1A, belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Precise m6A mapping by m6A-CLIP/IP (briefly m6A-CLIP) revealed that a majority of m6A locates in the last exon of mRNAs in multiple tissues/cultured cells of mouse and human, and the m6A enrichment around stop codons is a coincidence that many stop codons locate round the start of last exons where m6A is truly enriched. The methylation of adenosine is directed by a large m6A methyltransferase complex containing METTL3 as the SAM-binding sub-unit. Insulin-like growth factor-2 mRNA-binding proteins 1, 2, and 3 (IGF2BP1-3) are reported as a novel class of m6A readers. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
NSC100044
C11H15N5O4 (281.11239900000004)
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
2'-O-Methyladenosine
C11H15N5O4 (281.11239900000004)
2-O-Methyladenosine is a methylated adenine residue. 2-O-Methyladenosine is a naturally occurring 2-O-methylpurine nucleoside with long lasting hypotensive properties; resistance of 2-O-methyladenosine against adenosine deaminase is thought to contribute to prolonged activity. 2-O-Methyladenosine occurs in human fluids, and they increase in urines of untreated adenosine deaminase (ADA) deficient patients (OMIM 608958). (PMID: 9539952, 6980397) [HMDB] 2-O-Methyladenosine is a methylated adenine residue. 2-O-Methyladenosine is a naturally occurring 2-O-methylpurine nucleoside with long lasting hypotensive properties; resistance of 2-O-methyladenosine against adenosine deaminase is thought to contribute to prolonged activity. 2-O-Methyladenosine occurs in human fluids, and they increase in urines of untreated adenosine deaminase (ADA) deficient patients (OMIM 608958). (PMID: 9539952, 6980397). 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities [1][2]. 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities [1][2].
N6-Methyladenosine
C11H15N5O4 (281.11239900000004)
N6-Methyladenosine is a methylated adenine residue. N6-Methyladenosine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820) [HMDB] N6-Methyladenosine is a methylated adenine residue. N6-Methyladenosine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
3'-O-Methyladenosine
C11H15N5O4 (281.11239900000004)
3-O-Methyladenosine is a methylated adenine residue. [HMDB] 3-O-Methyladenosine is a methylated adenine residue. (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol (Adenosine, 3'-O-methyl- (8CI)(9CI)) is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1].
1-Methyladenosin
C11H15N5O4 (281.11239900000004)
1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
O(6)-Methyl-2'-deoxyguanosine
C11H15N5O4 (281.11239900000004)
1-Methyladenosine
C11H15N5O4 (281.11239900000004)
1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
2-Dimethylamino-4-oxo-6-(L-threo-1,2,3-trihydroxypropyl)-3,4-dihydropteridin|Euglenapterin
C11H15N5O4 (281.11239900000004)
1-Methyladenosine
C11H15N5O4 (281.11239900000004)
A methyladenosine carrying a methyl substituent at position 1. CONFIDENCE standard compound; INTERNAL_ID 313 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
2-O-methyladenosine
C11H15N5O4 (281.11239900000004)
CONFIDENCE standard compound; INTERNAL_ID 312 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities [1][2]. 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities [1][2].
6-Methyladenosine
C11H15N5O4 (281.11239900000004)
N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
2-O-Methyladenosine
C11H15N5O4 (281.11239900000004)
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 5
N6-Methyladenosine
C11H15N5O4 (281.11239900000004)
CONFIDENCE standard compound; INTERNAL_ID 307 N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
L-METHYLADENOSINE
C11H15N5O4 (281.11239900000004)
1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents. 1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
1-Methyldesoxyguanosine; LC-tDDA; CE10
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; LC-tDDA; CE20
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; LC-tDDA; CE30
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; LC-tDDA; CE40
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE0; CorrDec
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE10; CorrDec
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE30; CorrDec
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE0; MS2Dec
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE30; MS2Dec
C11H15N5O4 (281.11239900000004)
N1-Methyladenosine; AIF; CE10; MS2Dec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE0; CorrDec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE10; CorrDec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE0; MS2Dec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE30; CorrDec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE10; MS2Dec
C11H15N5O4 (281.11239900000004)
1-Methyldesoxyguanosine; AIF; CE30; MS2Dec
C11H15N5O4 (281.11239900000004)
3-O-Methyladenosine
C11H15N5O4 (281.11239900000004)
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol (Adenosine, 3'-O-methyl- (8CI)(9CI)) is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1].
2-C-Methyladenosine
C11H15N5O4 (281.11239900000004)
2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC50 values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis[1][2].
cladribine related compound a (20 mg) (2-methoxy-2-deoxyadenosine)
C11H15N5O4 (281.11239900000004)
5-(2-Amino-6-methoxy-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
C11H15N5O4 (281.11239900000004)
2-Hydroxymethyl-5-(7-methylamino-3H-pyrazolo[4,3-D]pyrimidin-3-YL)-tetrahydro-furan-3,4-diol
C11H15N5O4 (281.11239900000004)
4-Imidazolmethylene-5-Imidazolone Chromophore
C11H15N5O4 (281.11239900000004)
O(6)-Methyl-2-deoxyguanosine
C11H15N5O4 (281.11239900000004)
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
cordysinin B
C11H15N5O4 (281.11239900000004)
A member of the class of adenosines that is adenosine in which the hydroxy group at position 2 is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.
2’-Deoxy-N1-methylguanosine
C11H15N5O4 (281.11239900000004)
2’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-ol
C11H15N5O4 (281.11239900000004)
(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(methoxymethyl)oxolane-3,4-diol
C11H15N5O4 (281.11239900000004)
5'-o-methyladenosine
C11H15N5O4 (281.11239900000004)
{"Ingredient_id": "HBIN011859","Ingredient_name": "5'-o-methyladenosine","Alias": "NA","Ingredient_formula": "C11H15N5O4","Ingredient_Smile": "COCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O","Ingredient_weight": "281.27 g/mol","OB_score": "22.44657067","CAS_id": "NA","SymMap_id": "SMIT08694","TCMID_id": "NA","TCMSP_id": "MOL007215","TCM_ID_id": "NA","PubChem_id": "6480505","DrugBank_id": "NA"}
(1s,2s)-1-[2-(dimethylamino)-4-hydroxypteridin-6-yl]propane-1,2,3-triol
C11H15N5O4 (281.11239900000004)
1-[2-(dimethylamino)-4-hydroxypteridin-6-yl]propane-1,2,3-triol
C11H15N5O4 (281.11239900000004)
3-hydroxy-2,6,8-trimethyl-4a-(2-oxopropyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione
C11H15N5O4 (281.11239900000004)